optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo
Company profile
Ticker
OPTN
Exchange
Website
CEO
Peter Miller
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OptiNose US, Inc. • Optinose UK, Ltd. ...
OPTN stock data
Latest filings (excl ownership)
8-K
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 Feb 24
8-K
Entry into a Material Definitive Agreement
21 Dec 23
8-K
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
6 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Transcripts
OPTN
Earnings call transcript
2023 Q4
7 Mar 24
OPTN
Earnings call transcript
2023 Q3
9 Nov 23
OPTN
Earnings call transcript
2023 Q2
10 Aug 23
OPTN
Earnings call transcript
2023 Q1
11 May 23
OPTN
Earnings call transcript
2022 Q4
7 Mar 23
OPTN
Earnings call transcript
2022 Q3
10 Nov 22
OPTN
Earnings call transcript
2022 Q2
13 Aug 22
OPTN
Earnings call transcript
2022 Q1
12 May 22
OPTN
Earnings call transcript
2021 Q4
8 Mar 22
OPTN
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
4
Anthony J Krick
19 Mar 24
4
Michael F Marino III
19 Mar 24
4
Ramy A Mahmoud
19 Mar 24
4
Anthony J Krick
29 Feb 24
4
Paul Jr. Spence
29 Feb 24
4
Michael F Marino III
29 Feb 24
4
Ramy A Mahmoud
29 Feb 24
SC 13G/A
Rosalind Advisors, Inc.
22 Feb 24
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 66.85 mm | 66.85 mm | 66.85 mm | 66.85 mm | 66.85 mm | 66.85 mm |
Cash burn (monthly) | 1.49 mm | (no burn) | 564.67 k | 2.38 mm | 1.48 mm | 3.76 mm |
Cash used (since last report) | 10.11 mm | n/a | 3.84 mm | 16.18 mm | 10.02 mm | 25.54 mm |
Cash remaining | 56.73 mm | n/a | 63.01 mm | 50.66 mm | 56.83 mm | 41.30 mm |
Runway (months of cash) | 38.1 | n/a | 111.6 | 21.3 | 38.5 | 11.0 |
Institutional ownership, Q2 2023
82.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 16 |
Closed positions | 17 |
Increased positions | 22 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 69.22 bn |
Total shares | 92.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FMR | 14.80 mm | $18.21 bn |
Avista Capital Partners II GP | 14.27 mm | $23.12 mm |
MVM Partners | 12.50 mm | $20.25 mm |
Great Point Partners | 8.84 mm | $10.87 bn |
Acorn Bioventures | 6.74 mm | $11.93 mm |
Bleichroeder | 4.05 mm | $4.98 bn |
BLK Blackrock | 3.90 mm | $4.80 bn |
Kingdon Capital Management, L.L.C. | 3.65 mm | $4.49 bn |
Velan Capital Investment Management | 3.60 mm | $4.42 bn |
Vanguard | 3.59 mm | $4.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Anthony J Krick | Common Stock | Sell | Dispose S | No | No | 1.88 | 2,345 | 4.41 k | 143,988 |
18 Mar 24 | Michael F Marino III | Common Stock | Sell | Dispose S | No | No | 1.88 | 15,059 | 28.31 k | 602,268 |
18 Mar 24 | Ramy A Mahmoud | Common Stock | Sell | Dispose S | No | No | 1.88 | 19,198 | 36.09 k | 1,331,278 |
15 Mar 24 | Michael F Marino III | Common Stock | Grant | Acquire A | No | No | 0 | 3,816 | 0.00 | 617,327 |
15 Mar 24 | Ramy A Mahmoud | Common Stock | Grant | Acquire A | No | No | 0 | 6,114 | 0.00 | 1,350,476 |
28 Feb 24 | Anthony J Krick | Common Stock | Grant | Acquire A | No | No | 0 | 112,500 | 0.00 | 146,333 |
28 Feb 24 | Anthony J Krick | Stock Option Common Stock | Grant | Acquire A | No | No | 1.815 | 56,250 | 102.09 k | 56,250 |
28 Feb 24 | Paul Jr. Spence | Common Stock | Grant | Acquire A | No | No | 0 | 252,675 | 0.00 | 252,675 |
28 Feb 24 | Paul Jr. Spence | Stock Option Common Stock | Grant | Acquire A | No | No | 1.815 | 126,338 | 229.30 k | 126,338 |
News
Lake Street Maintains Buy on OptiNose, Raises Price Target to $4
18 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
HC Wainwright & Co. Initiates Coverage On OptiNose with Buy Rating, Announces Price Target of $5
11 Mar 24
OptiNose Q4 GAAP EPS $(0.09), Inline, Sales $19.86M Beat $19.23M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Press releases
Optinose to Present at the Needham Virtual Healthcare Conference
4 Apr 24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 Mar 24
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
14 Mar 24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
7 Mar 24
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29 Feb 24